Medicenna Therapeutics
Dan Scarr is an accomplished finance and corporate development professional with a diverse background that includes significant roles in both the biotechnology and investment sectors. Currently serving as Associate Director of Corporate Development & Finance at Medicenna Therapeutics Corp. since January 2024, Dan focuses on business development, finance strategy, and capital markets. As Chief Investment Officer and an Alumni Advisor at the Queen's University Alternative Assets Fund, Dan manages a portfolio of $700,000 AUM and advises on investment strategies, risk management, and analyst training. Previous experience includes an Investment Analyst position at Tri-Colour Venture Fund and Senior Research Analyst at Mount Sinai Hospital, contributing to numerous publications and presentations. Dan holds an MBA from the Smith School of Business at Queen's University and advanced degrees in Medical Clinical Sciences and Biochemistry.
This person is not in any teams
This person is not in any offices
Medicenna Therapeutics
1 followers
Medicenna Therapeutics is a clinical-stage immunotherapy company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs). Their mission is to become the leader in the development and commercialization of targeted ECs and Superkines for the treatment of a broad range of cancers and immune-mediated diseases.